MEK inhibitors in non-V600 BRAF mutations and fusions
Metrics: PDF 1654 views | Full Text 2404 views | ?
Douglas B. Johnson1, Caroline A. Nebhan1 and Marcus S. Noel2
1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA
2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
|Douglas B. Johnson,||email:||[email protected]|
Keywords: trametinib; MEK; BRAF; atypical; fusion
Received: October 09, 2020 Accepted: October 13, 2020 Published: November 03, 2020
Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.